Navigation Links
Peripheral Arterial Disease to be Treated With New Medicated Stent in Trial at Montefiore
Date:10/15/2007

New Treatment Could Benefit Millions Who Suffer From Condition

NEW YORK, Oct. 15 /PRNewswire-USNewswire/ -- The first trial to test whether medicated, drug-eluting (dispensing), stents can benefit patients who suffer from peripheral arterial disease (PAD) is taking place at Montefiore Medical Center, one of only 80 sites around the world joining in the study.

Medicated, drug-coated stents have been used with great success for the past several years in treating coronary artery disease.

PAD affects more than 10 million Americans, according to the Peripheral Arterial Disease (P.A.D.) Coalition. The disease restricts circulation in blood vessels that lead from the heart to other areas of the body, such as the legs and feet. Often undiagnosed, PAD results in pain when walking and can lead to gangrene and amputation. It also may signal an increased risk for coronary arterial disease and other related circulatory conditions.

"This is an exciting trial since it is the first evaluation of a drug- eluting stent in blood vessels outside the heart," said Evan Lipsitz, MD, chief of Vascular Surgery at Montefiore and principal investigator of the study. "Combining a stent designed to hold blood vessels open to allow blood to flow freely through the vessel, with a medication used to prevent renarrowing, may reduce the development of scar tissue, the primary cause of the stent failure, in the months following balloon angioplasty in leg arteries.

This helps eliminate the need for more invasive treatment, such as bypass surgery," Dr. Lipsitz said.

The stent is coated with paclitaxel, a drug derived from the Pacific yew tree that has been used successfully to reduce the risk of renarrowing of arteries.

The trial is designed to determine the safety and effectiveness of the Zilver(R) PTXTM drug-eluting stent in treating blockages in the femoropoliteal artery, the major artery in the thigh.

Montefiore Medical Center, The University Hospital and Academic Medical Center for the Albert Einstein College of Medicine, encompasses 125 years of innovative medical "firsts," pioneering clinical research, dedicated community service and ground-breaking social activism.

A full-service, integrated delivery system caring for patients from New York, Westchester County and beyond, Montefiore is a 1,122-bed medical center that includes three hospitals: the Henry and Lucy Moses Division, the Jack D. Weiler Hospital and The Children's Hospital at Montefiore; a large home healthcare agency; the first and largest school health program in the U.S.; a 21-site medical group practice integrated throughout the Bronx and Westchester; and a care management organization providing services to 179,000 health plan members.

The medical center is ranked by the prestigious Leapfrog Group among the top one percent of all U.S. hospitals based on its strategic investments in sophisticated and integrated healthcare technology

Montefiore's distinguished centers of excellence include cardiology and cardiac surgery, cancer care, tissue and organ transplantation, children's health, women's health, obesity, diabetes, surgery and the surgical subspecialties. Montefiore is a leader in the treatment of headaches, cough and sleep disorders, geriatrics and geriatric psychiatry, neurology and neurosurgery, bioethics, adolescent and family medicine, HIV/AIDS and social medicine, among many other specialties.


'/>"/>
SOURCE Montefiore Medical Center
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
2. AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic Peripheral Neuropathic Pain at International Congress on Neuropathic Pain
3. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
4. AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic Peripheral Neuropathic Pain at Second International Congress on Neuropathic Pain
5. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
6. Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
7. REACH Registry Demonstrates That Multiple Arterial Disease Locations Sharply Increase the Risk of Major CV Events in Outpatients With Atherothrombosis
8. Appendicitis: Evolving Tools to Diagnose a Classic Disease
9. Non-Invasive Diagnostic Tests for Celiac Disease
10. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Research and Markets has announced the addition of ... report to their offering. ... The World Market for Companion Diagnostics covers the world market ... the report includes the following: , World ... Region (N. America, EU, ROW), 2015-2020 , World IVD ...
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are confused ... endometriosis. These women need a treatment plan to not only alleviate symptoms and ... help for preservation of fertility and ultimately achieving a pregnancy. The specialists at ...
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
Breaking Medicine News(10 mins):